about
Sulfation of colonic mucins by N-acetylglucosamine 6-O-sulfotransferase-2 and its protective function in experimental colitis in miceBlood group antigen-targeting peptide suppresses anti-blood group antibody binding to antigen in renal glomerular capillaries after ABO-incompatible blood reperfusion.Serum N-glycan alteration associated with renal cell carcinoma detected by high throughput glycan analysis.Production of hybrid-IgG/IgA plantibodies with neutralizing activity against Shiga toxin 1.Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer.Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer.Tumor targeting by a carbohydrate ligand-mimicking peptide.Establishment of recombinant hybrid-IgG/IgA immunoglobulin specific for Shiga toxin.Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-scBK virus-associated urothelial carcinoma of a ureter graft in a renal transplant recipient: a case report.Outcome comparison of ABO-incompatible kidney transplantation with low-dose rituximab and ABO-compatible kidney transplantation: a single-center experience.Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.Renal cell carcinoma detected by preoperative kidney transplant donor examination: a case report.Serum N-glycan profiling predicts prognosis in patients undergoing hemodialysis.Carboplatin-based combination chemotherapy for elderly patients with advanced bladder cancer.Influence of local treatments with capsaicin or allyl isothiocyanate in the sensitization phase of a fluorescein-isothiocyanate-induced contact sensitivity model
P50
Q33673855-0507AE75-1B4E-475E-A467-468CD150AF04Q34527472-96264FFD-323E-4316-A9FF-6B3B3151D1CFQ35021015-6B30C15F-F0AB-4D80-9660-04F000E28A6BQ35060348-48B3A424-42BC-4886-9969-DE9ECCD3C2A0Q37735161-DF477D12-1C96-4EC4-BFC2-982FFBACC013Q38996524-4657B3F2-E8A4-4BE9-80BA-E809FFAA7FA3Q39139810-5287BA21-285B-42D5-9656-70C2886528C9Q39480986-0E9E9540-D25A-4C30-B4C5-43D1EDA3BFFFQ39563575-50C854F2-2D75-49C9-91CB-ECC893CAD1D2Q42229841-B5A39F34-2C75-4C54-89EF-A073F49CC449Q42229870-A5FDDDE2-0F6E-4E33-8AF6-8BFCA6E5DCE8Q43523307-30E9FB55-EF79-4593-96CE-B6E4F02A9FE2Q53073999-FFD10E2E-7A20-46A8-A0C4-B688ED87617AQ54335132-B9D5B98D-8099-497A-A554-8F6C7BB1E6B7Q54770311-82A6474A-BF74-4EEF-9B49-EDE837F1E6A1Q79679360-67431CB6-CBF4-475C-A544-9EB4282CD2D8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Yuki Tobisawa
@ast
Yuki Tobisawa
@en
Yuki Tobisawa
@es
Yuki Tobisawa
@nl
Yuki Tobisawa
@sl
type
label
Yuki Tobisawa
@ast
Yuki Tobisawa
@en
Yuki Tobisawa
@es
Yuki Tobisawa
@nl
Yuki Tobisawa
@sl
prefLabel
Yuki Tobisawa
@ast
Yuki Tobisawa
@en
Yuki Tobisawa
@es
Yuki Tobisawa
@nl
Yuki Tobisawa
@sl
P1053
G-3802-2014
P106
P31
P3829
P496
0000-0001-8026-9541